FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology, medicine and molecular biology. Disclosed is a new recombinant cell line of human breast cancer BrCCh4e-134, expressing prostate-specific membrane antigen (PSMA). BrCCh4e-134 cell line is obtained by transducing the BrCCh4e cell line with lentiviral particles preliminarily obtained by using calcium-phosphate transfection of the HEK293T cell line with a recombinant lentiviral plasmid pCDH-EF1a-PSMA-IRES-zeo. Presented cell line is intended for testing the activity of anti-tumor and anti-metastatic PSMA-targeted preparations.
EFFECT: invention widens the range of PSMA-positive cell lines possessing tumorigenicity and metastasis ability.
1 cl, 4 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT CYTO-CAR-YT-LACT CELL LINE EXHIBITING HIGH CYTOTOXIC ACTIVITY WITH RESPECT TO PSCA-POSITIVE HUMAN CANCER CELLS | 2019 |
|
RU2724431C1 |
| PSCA-CAR-YT CELL LINE HAVING SURFACE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND EXHIBITING CYTOTOXIC ACTIVITY ON PSCA-POSITIVE HUMAN CANCER CELLS | 2018 |
|
RU2712901C1 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| HUMAN BREAST CANCER CELL LINE BrCCh4e | 2019 |
|
RU2717654C1 |
| RECOMBINANT EL1 PEPTIDE HAVING CYTOTOXIC ACTIVITY RELATIVE TO HUMAN CANCER CELLS | 2017 |
|
RU2683221C1 |
| MOUSE HYBRIDOMA AMACR, CLONE G8 - PRODUCER OF MONOCLONAL ANTIBODY HAVING SPECIFICITY TO ALPHA-METHYLACYL-COENZYME RACEMASE (AMACR) OF HUMAN | 2016 |
|
RU2636042C1 |
| PHARMACEUTICAL FORMULATION FOR METASTASIS PREVENTION AND INCREASING OF TUMOUR SENSITISATION TO CHEMOTHERAPEUTIC AGENTS | 2007 |
|
RU2328282C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| METHOD OF ASSESSING THE SPECIFICITY OF BIOLOGICAL MOLECULES IN VITRO | 2022 |
|
RU2798541C1 |
| LYOPHILISATE BASED ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS FOR PREPARING A RADIOPHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTIONS FOR TREATING PROSTATE CANCER, RADIOPHARMACEUTICAL COMPOSITION BASED ON IT FOR TREATING PROSTATE CANCER AND METHOD FOR PREPARING RADIOPHARMACEUTICAL COMPOSITION | 2023 |
|
RU2817970C1 |
